BJ Bormann
Independent, Non-executive Board Member: The Jackson Laboratory
BJ Bormann is a professional with nearly 30 years of experience in academic and pharmaceutical science and biotechnology and pharmaceutical business development. She currently serves as the Vice President of Translational Science and Network Alliances for the Jackson Laboratory. In this role, Dr. Bormann is working to bring the innovations from the Jackson Laboratory faculty closer to patients by generating a series of collaborative relationships with industrial partners. Dr. Bormann’s previous work in the biotechnology area includes serving as CEO of Pivot Pharmaceuticals (OTC: PVOTF) as well as CEO of Supportive Therapeutics, LLC, a company developing a drug for the treatment of oral mucositis, a severe side effect to chemoradiation treatment in oncology patients.
Dr. Bormann has previously served as the CEO of Harbour Antibodies, based in the Netherlands, licensing transgenic mice that make human antibodies, as well as the Chief Business Advisor for NanoMedical Systems, Inc. of Austin, Texas, which licenses a unique implantable drug delivery device. Prior to these engagements, from 2007–2013, Dr. Bormann was Senior Vice President at Boehringer Ingelheim Pharmaceuticals, Inc., responsible for worldwide alliances, licensing, and business development. From 1996– 2007, she served in a number of positions at Pfizer, Inc., the last one being Vice President of Pfizer Global Research and Development and the worldwide Head of Strategic Alliances.
Dr. Bormann currently serves on the board of directors of various companies, including Supportive Therapeutics, LLC, the Institute for Pediatric Innovation, and Bioline RX (Nasdaq: BLRX). Dr. Bormann received her PhD in Biomedical Sciences from the University of Connecticut Health Center and her BS in Biology from Fairfield University. Dr. Bormann completed postdoctoral training at the Yale School of Medicine in the department of Pathology.
Committee Roles:
Chair of the Compensation Committee
Member of the Audit Committee
Dr. Bormann has previously served as the CEO of Harbour Antibodies, based in the Netherlands, licensing transgenic mice that make human antibodies, as well as the Chief Business Advisor for NanoMedical Systems, Inc. of Austin, Texas, which licenses a unique implantable drug delivery device. Prior to these engagements, from 2007–2013, Dr. Bormann was Senior Vice President at Boehringer Ingelheim Pharmaceuticals, Inc., responsible for worldwide alliances, licensing, and business development. From 1996– 2007, she served in a number of positions at Pfizer, Inc., the last one being Vice President of Pfizer Global Research and Development and the worldwide Head of Strategic Alliances.
Dr. Bormann currently serves on the board of directors of various companies, including Supportive Therapeutics, LLC, the Institute for Pediatric Innovation, and Bioline RX (Nasdaq: BLRX). Dr. Bormann received her PhD in Biomedical Sciences from the University of Connecticut Health Center and her BS in Biology from Fairfield University. Dr. Bormann completed postdoctoral training at the Yale School of Medicine in the department of Pathology.
Committee Roles:
Chair of the Compensation Committee
Member of the Audit Committee